Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide Extension in Early Parkinson's Disease
NCT01028586Phase 3Terminated
- Sponsor
- Newron Pharmaceuticals
- Start
- Oct 2009
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of safinamide in Parkinson's disease (PD), sponsored by Newron Pharmaceuticals. Started Oct 2009; status: terminated.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01028586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028586.